Dementia Action Week 2024, which starts today, shines a spotlight on Alzheimer’s disease, the most common cause of dementia.
The approval of several drugs for Alzheimer’s such as Eisai’s Leqembi (lecanemab) and Biogen’s Adhuelm (aducanumab), which was later withdrawn, in recent years has spurred activity in this space, not just for new drugs but also diagnostics.
Now, all eyes are on Eli Lily’s donanemab, which had positive data released from a Phase III study last year and is up for approval. In March 2024, the US Food and Drug Administration (FDA) requested an advisory committee meeting to get a ‘better grasp’ of the unique design of the Phase III TRAILBLAZER-ALZ 2 trial (NCT04437511), particularly how patients were selected based on levels of the tau protein.
